Show simple item record

dc.contributor.authorMateo, J
dc.contributor.authorPorta, N
dc.contributor.authorMcGovern, UB
dc.contributor.authorElliott, Tony
dc.contributor.authorJones, RJ
dc.contributor.authorSyndikus, I
dc.contributor.authorRalph, C
dc.contributor.authorJain, S
dc.contributor.authorVarughese, MA
dc.contributor.authorParikh, O
dc.contributor.authorCrabb, SJ
dc.contributor.authorMiranda, S
dc.contributor.authorSeed, G
dc.contributor.authorBertan, C
dc.contributor.authorEspinasse, A
dc.contributor.authorChatfield, P
dc.contributor.authorBianchini, D
dc.contributor.authorHall, E
dc.contributor.authorCarreira, S
dc.contributor.authorDe Bono, JS
dc.date.accessioned2019-11-19T16:01:06Z
dc.date.available2019-11-19T16:01:06Z
dc.date.issued2019en
dc.identifier.citationMateo J, Porta N, McGovern UB, Elliott T, Jones RJ, Syndikus I, et al. TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. J Clin Oncol. 2019;37(15_suppl):5005-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.5005en
dc.identifier.urihttp://hdl.handle.net/10541/622455
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5005en
dc.titleTOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterationsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Institute of Cancer Research & The Royal Marsden, Londonen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record